Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • aclidinium

    - PMLiVE

    Almirall and Absci expand AI dermatological drug discovery partnership

    The alliance has already led to the delivery of functional antibody leads against a difficult-to-drug target

    - PMLiVE

    GSK and Hengrui enter multi-programme collaboration agreement worth $12bn

    The deal includes a PDE3/4 inhibitor in clinical development for COPD

    - PMLiVE

    Merck to expand respiratory disease portfolio with $10bn Verona acquisition

    The deal includes a drug approved in the US for chronic obstructive pulmonary disease

    - PMLiVE

    Almirall hosts Skin Academy to advance skin science and dermatology treatments

    The conference will cover actinic keratosis, psoriasis, atopic dermatitis and other skin diseases

    - PMLiVE

    UK researchers uncover first new asthma and COPD attack treatment in 50 years

    The phase 2 study showed that benralizumab could be re-purposed for use in emergency settings

    - PMLiVE

    Eli Lilly/Almirall share positive long-term results for Ebglyss in atopic dermatitis

    The inflammatory skin condition occurs in approximately 7.3% of adults in the US

    - PMLiVE

    Sanofi/Regeneron’s Dupixent approved by MHRA to treat uncontrolled COPD

    Approximately 1.4 million people in the UK have been diagnosed with the respiratory disease

    - PMLiVE

    GSK announces positive late-stage results for IL-5 inhibitor Nucala in COPD

    The chronic respiratory disease affects more than 300 million people globally

    - PMLiVE

    Almirall announces NICE recommendation for Ebglyss in atopic dermatitis

    The inflammatory skin condition affects about 5.2 million adults and 2.5 million children in the UK

    - PMLiVE

    Sanofi/Regeneron’s Dupixent approved by EMA for uncontrolled COPD in adults

    Approximately 220,000 COPD patients in the EU could be eligible for Dupixent treatment

    - PMLiVE

    Almirall’s Ilumetri shown to improve and maintain well-being in plaque psoriasis patients

    Nearly 77% of psoriasis patients report that the condition negatively affects their well-being

    - PMLiVE

    Almirall’s Klisyri receives expanded FDA approval to treat actinic keratosis

    The precancerous condition is responsible for an estimated 60% of all squamous cell carcinoma cases

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links